• Latest
  • Trending
  • All
  • Featured Urology
  • Female Urology
  • Urologic Oncology
  • What is Urology?
  • Pediatric Urology
  • Urology

PSA Drop Seen with New Prostate Cancer Drug

September 8, 2020
Yoga for Prostate Cancer: Best Yoga exercises to combat prostate growth in men

Yoga for Prostate Cancer: Best Yoga exercises to combat prostate growth in men

November 14, 2022
New treatment can more than double life expectancy for people with prostate cancer: doctor

New treatment can more than double life expectancy for people with prostate cancer

November 14, 2022
Study finds that use of yoga app can reduce urinary incontinence

Study finds that use of yoga app can reduce urinary incontinence

November 9, 2022
Urinary Incontinence: Types and Treatments

Urinary Incontinence: Types and Treatments

November 9, 2022
Low Rates of PSA Screening Linked to Increase in Metastatic Prostate Cancer

Low Rates of PSA Screening Linked to Increase in Metastatic Prostate Cancer

November 4, 2022
Can Erectile Dysfunction Drugs Reduce Dementia Risk?

Can Erectile Dysfunction Drugs Reduce Dementia Risk?

November 4, 2022
New PSA test examines protein structures to detect prostate cancers

New PSA test examines protein structures to detect prostate cancers

November 2, 2022
A better way to image metastatic prostate cancer

A better way to image metastatic prostate cancer

November 2, 2022
Newly discovered protein may protect kidney cells from injury

Newly discovered protein may protect kidney cells from injury

November 2, 2022
A person’s diet, acidity of urine may affect susceptibility to UTIs

A person’s diet, acidity of urine may affect susceptibility to UTIs

November 2, 2022
Award-winning agent developed for prostate cancer diagnosis and treatment

Award-winning agent developed for prostate cancer diagnosis and treatment

November 2, 2022
New treatment for polycystic kidney disease

New treatment for polycystic kidney disease

November 2, 2022
Tuesday, November 22, 2022
Urology Today
  • Home
  • Featured Urology
    Yoga for Prostate Cancer: Best Yoga exercises to combat prostate growth in men

    Yoga for Prostate Cancer: Best Yoga exercises to combat prostate growth in men

    Study finds that use of yoga app can reduce urinary incontinence

    Study finds that use of yoga app can reduce urinary incontinence

    Urinary Incontinence: Types and Treatments

    Urinary Incontinence: Types and Treatments

    Low Rates of PSA Screening Linked to Increase in Metastatic Prostate Cancer

    Low Rates of PSA Screening Linked to Increase in Metastatic Prostate Cancer

    Kidney failure impacts survival of sepsis patients

    Kidney failure impacts survival of sepsis patients

    Urine-based test improves on PSA for detecting prostate cancer

    Urine-based test improves on PSA for detecting prostate cancer

    Unemployment linked to rise in prostate cancer deaths

    Unemployment linked to rise in prostate cancer deaths

    Unemployment linked to rise in prostate cancer deaths

    Advanced viral gene therapy eradicates prostate cancer in preclinical experiments

    prostate cancer

    Recurrence of prostate cancer detected earlier with innovative PSMA-ligand PET/CT

    Two major studies strengthen case for prostate cancer drug before chemotherapy

    Two major studies strengthen case for prostate cancer drug before chemotherapy

    Trending Tags

    • Donald Trump
    • Future of News
    • Climate Change
    • Market Stories
    • Election Results
    • Flat Earth
  • Lifestyle
    • All
    • Female Urology
    • Male Urology
    • Pediatric Urology
    Yoga for Prostate Cancer: Best Yoga exercises to combat prostate growth in men

    Yoga for Prostate Cancer: Best Yoga exercises to combat prostate growth in men

    Study finds that use of yoga app can reduce urinary incontinence

    Study finds that use of yoga app can reduce urinary incontinence

    Urinary Incontinence: Types and Treatments

    Urinary Incontinence: Types and Treatments

    New PSA test examines protein structures to detect prostate cancers

    New PSA test examines protein structures to detect prostate cancers

    A better way to image metastatic prostate cancer

    A better way to image metastatic prostate cancer

    Award-winning agent developed for prostate cancer diagnosis and treatment

    Award-winning agent developed for prostate cancer diagnosis and treatment

    New treatment for polycystic kidney disease

    New treatment for polycystic kidney disease

    Urine-based test improves on PSA for detecting prostate cancer

    Urine-based test improves on PSA for detecting prostate cancer

    Unemployment linked to rise in prostate cancer deaths

    Advanced viral gene therapy eradicates prostate cancer in preclinical experiments

    Two major studies strengthen case for prostate cancer drug before chemotherapy

    Two major studies strengthen case for prostate cancer drug before chemotherapy

    Trending Tags

    • Golden Globes
    • Mr. Robot
    • MotoGP 2017
    • Climate Change
    • Flat Earth
No Result
View All Result
Urology Today
No Result
View All Result
Home Urology / Nephrology News

PSA Drop Seen with New Prostate Cancer Drug

by Urology Today
September 8, 2020
in Urology / Nephrology News
0
491
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter

Half of a group of men with castration-resistant prostate cancer (CRPC) had biochemical responses to treatment with an investigational androgen receptor modulator, data from a preliminary clinical study showed.

During 12 weeks of treatment with galeterone, prostate-specific antigen (PSA) declined by at least 30% in 24 of 49 patients, 11 of whom had declines of 50% or more.

The single agent was generally well tolerated, with only one serious adverse effect was attributed to galeterone, R. Bruce Montgomery, MD, reported here at the American Association for Cancer Research (AACR) meeting.

“There was evidence of on-target effects by suppressing PSA in an androgen-regulated tumor,” said Montgomery, of the University of Washington in Seattle, during an AACR press briefing. There have been at least three radiographic responses, and we continue to that information.”

Galeterone is a semisynthetic steroid analog that targets three aspects of prostate cancer cell proliferation and survival. The drug inhibits CYP17 lyase, a key enzyme in the steroidogenic pathway involved in androgen production. The recently approved drug abiraterone (Zytiga) also targets CYP17 lyase.

Galeterone also inhibits androgen-receptor binding, the principal mechanism of action for bicalutamide and the investigational agent MDV3100.

Unlike other drugs approved for CRPC or in clinical development, galeterone disrupts prostate cancer cells’ internal androgen-receptor production.

The euphemistic term castration-resistant prostate cancer (CRPC) has slowly entered the everyday lexicon of those who study and treat prostate cancer. Ahmann and Crawford utilized this term in 1987. Emanating from what used to be called hormone-refractory prostate cancer and/or androgen-independent prostate cancer, this CRPC consensus definition was first formally reintroduced at a 2005 ODAC discussion on prostate cancer trial end points. Subsequently, in 2008, it was specifically defined in a Prostate Cancer Working Group Guidelines report, published in Journal of Clinical Oncology.

At that time, Scher et al recognized that despite medical or surgical castration, prostate cancers were still sensitive to subcastrate levels of androgens, either emanating from the adrenal cortex or from prostate cancer cells themselves (with direct intracrine activation of the androgen receptor cascade).

However, there have been some concerns expressed by clinicians, and more importantly by patients themselves, that the term castration implies some sort of testicular removal, which has a negative connotation for many men who have this disease.

Hormone-refractory prostate cancer and androgen-independent prostate cancer did not have this perceived stigma, but in contrast, they have proven to be considerably inaccurate, as second-generation androgen deprivation therapy clinical trials are beginning to demonstrate.

Therefore, we would like to propose that a term such as endocrine-resistant prostate cancer may be a better description to utilize with our colleagues and patients. It is both accurate and less emotionally charged. Seen in this fashion, it gives us in the field, as well as our patients, a clearer way to view therapeutic options (which will increase significantly in the years to come).

Therapeutically, if patients knew their disease was either endocrine sensitive or endocrine resistant, potentially approvable agents like Abiraterone, MDV-3100, and even estrogenic compounds could be clearly delineated from the evolving nonhormonal options that are also coming down the pike, like immunotherapy, targeted agents, and newer chemotherapies.

Montgomery reported findings from a phase I dose-finding study involving men with disease progression during androgen ablation therapy, but no prior chemotherapy. Participants were randomized to eight dose-escalation cohorts that received single or split daily doses ranging from 650 to 2,600 mg/d.

After 12 weeks of treatment, patients could enter an extension phase if they met certain eligibility criteria. The primary objective was to evaluate galeterone’s safety, but a preliminary efficacy assessment also was performed.

Chemotherapy in castrate-resistant prostate cancer
For men with metastatic prostate cancer, hormonal therapy usually provides disease control for a substantial period of time. However, the vast majority eventually develop progressive disease that is resistant to further hormone manipulation.

Until recently, cytotoxic chemotherapy was considered to be relatively ineffective in men with castrate-resistant prostate cancer. In early trials, objective response rates were 10 to 20 percent, and median survival generally did not exceed 12 months. However, regimens that include docetaxel have been associated with higher rates of both objective tumor regression and biochemical (prostate specific antigen [PSA]) response, as well as longer survival durations.

The use of cytotoxic chemotherapy for the treatment of castrate-resistant prostate cancer will be reviewed here, with a focus on taxanes, mitoxantrone, and estramustine, as well as new chemotherapy agents under development. An overview of other aspects of the management of advanced prostate cancer is presented separately.

Grade 1 and 2 adverse events occurred in 58% and 30%, respectively, of the study population. The most common adverse events were:

  Fatigue: 36.7%
  Abnormal liver function tests: 32.7% for aspartate transaminase (AST) and 30.6% for alanine transaminase (ALT)
  Nausea: 28.6%
  Diarrhea: 26.5%
  Pruritis 24.5%

{pagebreak}

Transient grade 2-3 liver-enzyme elevations occurred in 15 patients, 11 of whom required dose interruptions, Montgomery reported. Seven patients resumed treatment with galeterone, and all but one of them completed treatment without recurrent grade 3+ liver-enzyme elevations.

“The transaminitis was not dose related and was very transient,” Montgomery said.

Nine patients had serious adverse events, one linked to galeterone treatment: grade 4 rhabdomyolysis in a patient with renal insufficiency and taking simvastatin (Zocor). No cases of adrenal mineralocorticoid excess were observed.

Prostate cancer is now the most common cancer in Australia – even if women are included in the denominator – and represents 14.5% of all cancers. In comparison, colorectal cancer accounts for 13.5% of cancers in Australia and breast cancer for 12.8%. Prostate cancer is an Australian National Health Priority Area. Its incidence is increasing, probably due to improved diagnosis of early-stage disease, but to date no convincing reduction in mortality has accompanied the pattern of early diagnosis. When prostate cancer is confined to the prostate it is potentially curable; therefore, considerable activity is currently being devoted to improving primary therapies for localised prostate cancer, including newer surgical techniques or the application of new radiotherapy techniques, such as intensitymodulated radiotherapy (IMRT) or image-gated radiotherapy (IGRT). However, once prostate cancer has spread to other tissues, it is generally incurable and treatment is usually palliative in intent. Most clinical research in the latter setting has involved the use of cytotoxic chemotherapy; however, recent insights into the biology of prostate cancer have provided clues to new therapeutic possibilities.

More than 30 patients had some degree of biochemical response to galeterone, which included the 24 who had declines in PSA levels of 30% or more. The magnitude of reduction increased with the dose of galeterone.

The drug currently is undergoing reformulation to optimize pharmacokinetics and pharmacodynamics. Montgomery said the reformulation was undertaken because investigators did not observe dose proportionality in the study and because the maximum tolerated dose was identified at the doses evaluated in the trial.

A phase II clinical trial is planned for the second half of 2012, using the new formulation.

Montgomery had no relevant disclosures.

Primary source: American Association for Cancer Research
Source reference: Taplin ME, et al. “Safety of galeterone (TOK-001) in a phase I clinical trial in chemotherapy-naive patients with castration-resistant prostate cancer (CRPC)” AARC 2012;abstract CT-07.

Share196Tweet123Share49
Urology Today

Urology Today

  • Trending
  • Comments
  • Latest

Urethral pressure profilometry

September 8, 2020
Low Rates of PSA Screening Linked to Increase in Metastatic Prostate Cancer

Low Rates of PSA Screening Linked to Increase in Metastatic Prostate Cancer

November 4, 2022
Embryogenesis -Paediatric Urology

Embryogenesis -Paediatric Urology

November 2, 2022

Genetic basis of genitourinary malformations

0
Embryogenesis -Paediatric Urology

Embryogenesis -Paediatric Urology

0
Upper urinary tract

Upper urinary tract

0
Yoga for Prostate Cancer: Best Yoga exercises to combat prostate growth in men

Yoga for Prostate Cancer: Best Yoga exercises to combat prostate growth in men

November 14, 2022
New treatment can more than double life expectancy for people with prostate cancer: doctor

New treatment can more than double life expectancy for people with prostate cancer

November 14, 2022
Study finds that use of yoga app can reduce urinary incontinence

Study finds that use of yoga app can reduce urinary incontinence

November 9, 2022
Urology Today

Copyright © 2022 Urology Today.

Navigate Site

  • About
  • Advertise
  • Privacy & Policy
  • Contact

Follow Us

No Result
View All Result
  • Home
  • Featured Urology
    • Urologic Oncology
    • Female Urology
    • Pediatric Urology
    • What is Urology?
  • Lifestyle

Copyright © 2022 Urology Today.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In